Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

May 31, 2006

Conditions
Anxiety Disorders
Interventions
DRUG

XBD173

Trial Locations (23)

30308

Investigational Site, Atlanta

33407

Investigational Site, West Palm Beach

33702

Investigational Site, St. Petersburg

33712

Investigational Site, Fort Meyers

37115

Investigational Site, Madison

38119

Investigational Site, Memphis

45408

Investigational Site, Dayton

60194

Investigational Site, Hoffman Estates

60523

Investigational Site, Oak Brook

66211

Investigational Site, Overland Park

90024

Investigational Site, Los Angeles

92108

Investigational Site, San Diego

92374

Investigational Site, Redlands

92660

Investigational Site, Newport Beach

92801

Investigational Site, Anaheim

97239

Investigational Site, Portland

T6G 2C8

Investigational Site, Edmonton

V1Y 2H4

Investigational Site, Kelowna

3Z5

Investigational Site, Hamilton

7K4

Investigational Site, Ottawa

1R8

Investigational Site, Toronto

2N6

Investigational Site, Montreal

4J6

Investigational Site, Sherbrooke

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY